IRIS
NAPOLITANO, Stefania
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 1.442
NA - Nord America 1.149
AS - Asia 219
AF - Africa 1
OC - Oceania 1
SA - Sud America 1
Totale 2.813
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.128
IE - Irlanda 592
IT - Italia 358
DE - Germania 135
GB - Regno Unito 100
SG - Singapore 94
CN - Cina 78
UA - Ucraina 65
FR - Francia 52
SE - Svezia 40
GR - Grecia 31
FI - Finlandia 23
CA - Canada 19
CZ - Repubblica Ceca 16
TR - Turchia 16
PK - Pakistan 14
BE - Belgio 12
IN - India 6
NL - Olanda 6
VN - Vietnam 6
AT - Austria 3
ES - Italia 3
MK - Macedonia 3
GI - Gibilterra 2
IR - Iran 2
MX - Messico 2
AR - Argentina 1
AU - Australia 1
BW - Botswana 1
HK - Hong Kong 1
HU - Ungheria 1
JP - Giappone 1
LK - Sri Lanka 1
Totale 2.813
Salva come PNG Salva come JPEG
Città #
Dublin 578
Chandler 282
Jacksonville 108
Naples 81
New York 72
Bremen 68
Princeton 66
Roxbury 66
Singapore 55
Caserta 39
Beijing 37
Cambridge 37
Ann Arbor 33
Medford 29
Wilmington 20
Brno 16
Elora 16
Ashburn 15
Boardman 14
Des Moines 14
Napoli 13
Brussels 12
Munich 12
Woodbridge 12
Lappeenranta 10
Houston 9
San Mateo 9
Milan 8
Rome 8
Dong Ket 6
Jinan 6
Los Angeles 6
Nanjing 6
Pozzuoli 6
Bahawalpur 5
Battipaglia 5
Düsseldorf 5
Menlo Park 5
Mountain View 5
Ercolano 4
Fairfield 4
Auburn Hills 3
Colle di Val d'Elsa 3
Helsinki 3
Madrid 3
Montecorvino Rovella 3
Montpellier 3
Nanchang 3
Norwalk 3
Sennori 3
Toronto 3
Venice 3
Viareggio 3
Vienna 3
Acerra 2
Alba Adriatica 2
Amsterdam 2
Anantapur 2
Andover 2
Avellino 2
Berlin 2
Castellammare di Stabia 2
Cinquevie 2
Corbara 2
Florence 2
Groningen 2
Gunzenhausen 2
Matera 2
Mexico 2
Molinella 2
Nola 2
Pune 2
San Nicola la Strada 2
Seattle 2
Shenyang 2
Skopje 2
Strasbourg 2
Antea 1
Bari 1
Bedizzole 1
Benevento 1
Bezons 1
Castellammare Di Stabia 1
Catania 1
Central 1
Cercola 1
Falconara Marittima 1
Forest City 1
Formello 1
Gaborone 1
Genova 1
Hangzhou 1
Hebei 1
Hyderabad 1
Jiaxing 1
Konya 1
Kunming 1
L'aquila 1
London 1
Lviv 1
Totale 1.910
Salva come PNG Salva come JPEG
Nome #
EPHA2 is a predictive biomarker of resistance and a potential therapeutic target for improving anti-epidermal growth factor receptor therapy in colorectal cancer 100
Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab. 85
Molecular aspects of resistance to biological and non-biological drugs and strategies to overcome resistance in colorectal cancer. 79
Clinical practice use of liquid biopsy to identify RAS/BRAF mutations in patients with metastatic colorectal cancer (mCRC): A single institution experience 79
Primary and Acquired Resistance of Colorectal Cancer Cells to Anti-EGFR Antibodies Converge on MEK/ERK Pathway Activation and Can Be Overcome by Combined MEK/EGFR Inhibition. 68
AXL is an oncotarget in human colorectal cancer 64
Eighth American Joint Committee on Cancer (AJCC) melanoma classification: what about stage IIC? 61
Increased TGF-α as a mechanism of acquired resistance to the anti-EGFR inhibitor cetuximab through EGFR-MET interaction and activation of MET signaling in colon cancer cells 58
Clinical outcome and molecular characterisation of chemorefractory metastatic colorectal cancer patients with long-term efficacy of regorafenib treatment 58
A case report of a severe fluoropyrimidine-related toxicity due to an uncommon DPYD variant 58
Comprehensive genome profiling by next generation sequencing of circulating tumor DNA in solid tumors: a single academic institution experience 58
Clinical outcome of patients with chemorefractory metastatic colorectal cancer treated with trifluridine/tipiracil (TAS-102): a single Italian institution compassionate use programme 53
MET ACTIVATION BY AUTOCRINE LOOP RESCUES COLON CANCER CELLS FROM SENSITIVITY TO EGFR INHIBITION 51
It is finally time for adjuvant therapy in melanoma 48
Present and future of metastatic colorectal cancer treatment: A review of new candidate targets 47
Regorafenib in combination with silybin as a novel potential strategy for the treatment of metastatic colorectal cancer 47
Liquid Biopsy at Home: Delivering Precision Medicine for Patients with Cancer During the Covid-19 Pandemic 47
Atypical haemolytic-uraemic syndrome in patient with metastatic colorectal cancer treated with fluorouracil and oxaliplatin: A case report and a review of literature 45
Dual inhibition of TGFβ and AXL as a novel therapy for human colorectal adenocarcinoma with mesenchymal phenotype 45
Which treatment after first line therapy in NSCLC patients without genetic alterations in the era of immunotherapy? 44
Anti-tumor activity of cetuximab plus avelumab in non-small cell lung cancer patients involves innate immunity activation: findings from the CAVE-Lung trial 44
Therapeutic value of EGFR inhibition in CRC and NSCLC: 15 years of clinical evidence. 43
Mechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancer 42
Genetic Landascape of Primary versus metastatic colorectal cancer: to what extent are they concordant ? 40
Antitumor efficacy of triple monoclonal antibody inhibition of epidermal growth factor receptor (EGFR) with MM151 in EGFRdependent and in cetuximab-resistant human colorectal cancer cells 39
Receptor tyrosine kinase-dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated human colorectal cancer cell lines 39
PRAME Immunocytochemistry for the Diagnosis of Melanoma Metastases in Cytological Samples 39
Optimal treatment strategy for metastatic melanoma patients harboring BRAF-V600 mutations 38
Gut microbiota correlates with antitumor activity in patients with mCRC and NSCLC treated with cetuximab plus avelumab 38
Maintenance Treatment with Cetuximab and BAY86-9766 Increases Antitumor Efficacy of Irinotecan plus Cetuximab in Human Colorectal Cancer Xenograft Models 37
Treatment of cutaneous melanoma harboring smo p.Gln216arg mutation with imiquimod: An old drug with new results 37
Dramatic Therapeutic Response to Dabrafenib Plus Trametinib in BRAF V600E Mutated Papillary Craniopharyngiomas: A Case Report and Literature Review 36
Mixed Neuroendocrine Non-Neuroendocrine Neoplasms of the Gastrointestinal Tract: A Case Series 36
Baseline IFN-γ and IL-10 expression in PBMCs could predict response to PD-1 checkpoint inhibitors in advanced melanoma patients 35
Vulnerability to low-dose combination of irinotecan and niraparib in ATM-mutated colorectal cancer 35
Biomarker-guided anti-egfr rechallenge therapy in metastatic colorectal cancer 35
Cetuximab rechallenge plus avelumab in pretreated patients with RAS Wild-type Metastatic Colorectal Cancer: The Phase 2 Single-Arm Clinical CAVE Trial 35
Immunotherapy for head and neck cancer: Present and future 35
Therapeutic efficacy of SYM004, a mixture of two anti-EGFR antibodies in human colorectal cancer with acquired resistance to cetuximab and MET activation 34
Multiple Acquired Mutations Captured by Liquid Biopsy in the EGFR Addicted Metastatic Colorectal Cancer 34
Multi-Omic Approaches in Colorectal Cancer beyond Genomic Data 34
Clinical Utility of Liquid Biopsy to Detect BRAF and NRAS Mutations in Stage III/IV Melanoma Patients by Using Real-Time PCR 33
Beyond N staging in colorectal cancer: Current approaches and future perspectives 33
How immunotherapy has changed the continuum of care in hepatocellular carcinoma 33
Comprehensive Review on the Clinical Relevance of Long Non-Coding RNAs in Cutaneous Melanoma 33
Impact of a cardio-oncology unit on prevention of cardiovascular events in cancer patients 33
Novel in vitro cancer models for optimizing anti- EGFR therapies 32
Pretreatment Plasma Circulating Tumor DNA RAS/BRAF Mutational Status in Refractory Metastatic Colorectal Cancer Patients Who Are Candidates for Anti-EGFR Rechallenge Therapy: A Pooled Analysis of the CAVE and VELO Clinical Trials 31
Triple blockade of EGFR, MEK and PD-L1 has antitumor activity in colorectal cancer models with constitutive activation of MAPK signaling and PD-L1 overexpression 30
Skin toxicity as predictor of survival in refractory patients with ras wild‐type metastatic colorectal cancer treated with cetuximab and avelumab (Cave) as rechallenge strategy 30
Immunotherapy in colorectal cancer: is the long-awaited revolution finally happening? 30
Clinical management of metastatic colorectal cancer in the era of precision medicine 30
CAVE-2 (Cetuximab-AVElumab) mCRC: A Phase II Randomized Clinical Study of the Combination of Avelumab Plus Cetuximab as a Rechallenge Strategy in Pre-Treated RAS/BRAF Wild-Type mCRC Patients 29
Real-world clinical outcome and safety of adjuvant therapy in stage III melanoma patients: Data from two Academic Italian Institutions 28
Combined blockade of MEK and PI3KCA as an effective antitumor strategy in HER2 gene amplified human colorectal cancer models 28
Feasibility of next-generation sequencing in clinical practice: Results of a pilot study in the Department of Precision Medicine at the University of Campania ' Luigi Vanvitelli' 27
Pimasertib hydrochloride 27
Resistance to anti-epidermal growth factor receptor in metastatic colorectal cancer: What does still need to be addressed? 24
Anti-EGFR-resistant clones decay exponentially after progression: Implications for anti-EGFR re-challenge 24
Current Landscape and Open Questions on Adjuvant Therapies in Melanoma 24
Clinical efficacy of sequential treatments in KRASG12C-mutant metastatic colorectal cancer: findings from a real-life multicenter Italian study (CRC-KR GOIM) 22
Real-World Activity and Safety of Trifluridine-Tipiracil Plus Bevacizumab Therapy in Patients with Refractory Metastatic Colorectal Cancer 22
Predictive Evaluation on Cytological Sample of Metastatic Melanoma: The Role of BRAF Immunocytochemistry in the Molecular Era 22
Antitumor efficacy of dual blockade with encorafenib plus cetuximab in combination with chemotherapy in human BRAFV600E mutant colorectal cancer 22
Towards the era of precision medicine in metastatic colorectal cancer 20
How we treat metastatic colorectal cancer 20
NMR profiling of Ononis diffusa identifies cytotoxic compounds against cetuximab-resistant colon cancer cell lines 19
Hypothalamic–pituitary autoimmunity in patients treated with anti-pd-1 and anti-pd-l1 antibodies 19
Evolving Strategies for the Management of BRAF-Mutant Metastatic Colorectal Cancer 19
Establishment of patient-derived tumor organoids to functionally inform treatment decisions in metastatic colorectal cancer 18
The Role of Sentinel Node Biopsy in the Era of Adjuvant Therapy for Melanoma 18
Correction: Ciardiello et al. Biomarker-Guided Anti-EGFR Rechallenge Therapy in Metastatic Colorectal Cancer. Cancers 2021, 13, 1941 18
Triple blockade of Ido-1, PD-L1 and MEK as a potential therapeutic strategy in NSCLC 17
Retrospective Study of Regorafenib Versus TAS-102 Efficacy and Safety in Chemorefractory Metastatic Colorectal Cancer (mCRC) Patients: A Multi-institution Real Life Clinical Data 17
Panitumumab Plus Trifluridine-Tipiracil as Anti-Epidermal Growth Factor Receptor Rechallenge Therapy for Refractory RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial 16
Final results of the CAVE trial in RAS wild type metastatic colorectal cancer patients treated with cetuximab plus avelumab as rechallenge therapy: Neutrophil to lymphocyte ratio predicts survival. 16
Post-Irradiation Breast Angiosarcoma: All the Possible Treatments and Electrochemotherapy. Case Report and Literature Review 14
Optimization of the Development of Old and New EGFR and MAP Kinase Inhibitors for Colorectal Cancer 14
Mechanisms of innate and acquired resistance to anti-EGFR therapy: A review of current knowledge with a focus on rechallenge therapies 14
Management of Non-Melanoma Skin Cancer: Radiologists Challenging and Risk Assessment 14
"RT STRIKES BACK": Radiotherapy in Ultra Elderly with Cutaneous Basal Cell Carcinoma 13
ITGB1 and DDR activation as novel mediators in acquired resistance to osimertinib and MEK inhibitors in EGFR-mutant NSCLC 13
Efficacy and safety of a biomarker-driven cetuximab-based treatment regimen over 3 treatment lines in mCRC patients with RAS/BRAF wild type tumors at start of first line: The CAPRI 2 GOIM trial 12
How can we manage the cardiac toxicity of immune checkpoint inhibitors? 12
Cetuximab as third-line rechallenge plus either irinotecan or avelumab is an effective treatment in metastatic colorectal cancer patients with baseline plasma RAS/BRAF wild-type circulating tumor DNA: Individual patient data pooled analysis of CRICKET and CAVE trials 9
The Role of Adjuvant Therapy for the Treatment of Micrometastases in Endometrial Cancer: A Systematic Review and Meta-Analysis 8
Resistance Mechanisms to Anti-Epidermal Growth Factor Receptor Therapy in RAS/RAF Wild-Type Colorectal Cancer Vary by Regimen and Line of Therapy 7
Sentinel node biopsy in thin melanoma: a retrospective descriptive cohort study 6
Magnetic Resonance Imaging Evaluation of Bone Metastases Treated with Radiotherapy in Palliative Intent: A Multicenter Prospective Study on Clinical and Instrumental Evaluation Assessment Concordance (MARTE Study) 5
MicroRNA Expression in Endometrial Cancer: Current Knowledge and Therapeutic Implications 4
Totale 2.989
Salva come PNG Salva come JPEG
Categoria #
all - tutte 15.082
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 15.082
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020206 30 21 11 9 16 6 34 10 27 26 12 4
2020/2021256 28 11 18 20 23 13 25 23 12 29 38 16
2021/2022514 15 13 6 4 105 15 38 15 30 59 64 150
2022/20231.193 127 18 32 96 149 97 5 66 545 9 33 16
2023/2024596 61 25 17 23 158 88 18 22 18 14 54 98
2024/202551 51 0 0 0 0 0 0 0 0 0 0 0
Totale 2.989